At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies
At SXSW, Mark Cuban and eMed CEO Linda Yaccarino announced a partnership that will route employer‑sponsored GLP‑1 weight‑loss prescriptions through Cuban’s Cost Plus Drugs. Yaccarino highlighted eMed’s 90 % one‑year retention rate, contrasting it with the 50‑60 % churn seen at direct‑to‑consumer players such as Ro and Hims & Hers. The collaboration emphasizes weekly digital check‑ins, facial‑recognition monitoring, and a joint effort to lower GLP‑1 prices. The move comes amid broader industry pressure to make costly obesity drugs more affordable, exemplified by TrumpRx coupons and Novo’s renewed ties with Hims & Hers.
Summit Midstream Corp (SMC) Q4 2025 Earnings Call Transcript
Summit Therapeutics reported a cash balance of $713 million and zero debt at year‑end, while GAAP operating expenses fell to $225 million. The FDA accepted its Biologics License Application for ivonesumab in EGFR‑mutant non‑small cell lung cancer, setting a PDUFA action date...
Monocyte Immune Shifts in HIV Patients on Injectable Therapy
Researchers published a longitudinal study showing that people living with HIV who switch from daily oral antiretrovirals to the long‑acting injectable combo cabotegravir‑rilpivirine experience an early, transient rise in monocyte activation followed by a sustained decline below baseline levels. Flow...
The Pink Pill: New Documentary Exposes the Long Battle to Bring Addyi — the First Libido Drug for Women —...
The documentary "The Pink Pill" chronicles the decade‑long fight to bring Addyi, the first FDA‑approved drug for women’s low libido, to market. Founder Cindy Eckert bought the rights after a major pharma abandoned the project, launched a 13,000‑patient trial, and...
The Lethal Cost of Regulatory Perfection in Rare Disease
During a congressional hearing, neurologists warned that rare disease patients are dying while therapies linger in FDA review. The FDA recently rejected the SCA drug troriluzole, demanding more statistical certainty despite trial data showing over 50% fall‑risk reduction. Congress has...
Rethinking Where Patient Recruitment Begins
Clinical trials have long relied on site‑based recruitment, leaving under‑ and misdiagnosed patients underrepresented. Recent studies show digital outreach can identify symptomatic individuals who never enter traditional healthcare pathways, dramatically expanding the eligible pool. Digital campaigns have cut cost per...
Lupin Taking Bigger Bets on Innovation, More Proprietary Products in India: Lupin MD
Lupin is pivoting toward proprietary new chemical entities (NCEs) in India, aiming to launch multiple innovative products by next year. The company plans to focus on cardiac, diabetes, respiratory and oncology molecules, leveraging lower development costs and faster time‑to‑market. AI...
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
Eli Lilly has launched Employer Connect, a platform that lets large employers purchase its weight‑loss injection Zepbound at a discounted $449 price, aiming to close the coverage gap that leaves over half of workers without obesity drug benefits. The program bypasses...
Japan Becomes First to Approve Stem Cell Therapies for Parkinson’s and Heart Failure
Japan has become the first country to grant conditional approval for two regenerative medicines that use induced pluripotent stem cells—AMCHEPRY for Parkinson’s disease and RiHEART for severe heart failure. The Parkinson’s therapy implants dopamine‑producing neurons into the brain, while the...
Wegovy Users May Have 5 Times Risk of Vision Loss than Those on Ozempic
Researchers analyzing over 30 million adverse‑event reports found that patients using Wegovy, the high‑dose semaglutide injection for obesity, have about five times the odds of developing ischemic optic neuropathy (ION) compared with those on Ozempic, the lower‑dose diabetes formulation. The association...
Most Insomnia Meds Don’t Worsen Sleep Apnea
A systematic review and network meta‑analysis of 32 randomized trials examined twelve hypnotic agents in adults with obstructive sleep apnea (OSA). The analysis found that most sleep‑inducing drugs do not worsen the apnea‑hypopnea index or oxygen saturation, challenging the long‑standing...
Re: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised, Open Label, Phase...
A phase‑3 BMJ trial reported that adding camrelizumab to standard chemoradiotherapy improved 36‑month progression‑free, distant‑metastasis‑free and locoregional‑recurrence‑free survival in high‑risk nasopharyngeal carcinoma. The protocol combined two concurrent cycles with 17 adjuvant cycles, yet only 61.9% of patients completed the full...
Zydus Lifesciences’ Anaemia Drug Desidustat Gets China Approval
Zydus Lifesciences has received NMPA approval for its oral anaemia drug Desidustat, targeting renal anaemia in adult chronic kidney disease patients who are not on dialysis. The therapy, a hypoxia‑inducible factor‑prolyl hydroxylase inhibitor, demonstrated efficacy and safety in Chinese Phase III...
A Lab Mistake at Cambridge Reveals a Powerful New Way to Modify Drug Molecules
Cambridge chemists have unveiled a light‑driven “anti‑Friedel‑Crafts” reaction that forms carbon‑carbon bonds using only LED illumination at ambient temperature. The metal‑free method allows precise, late‑stage modifications of complex drug molecules, cutting months of multistep synthesis. Tested on a broad set...
Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment
Pretzel Therapeutics presented preclinical data for its investigational small‑molecule PX578 at the 2026 MDA Clinical and Scientific Conference. The drug is designed to activate the mitochondrial DNA polymerase gamma (POLG) and restore mitochondrial DNA levels in patients with mitochondrial DNA...
What’s New Pussycat? FDA Assists Drug Sponsors Requesting New Clinical Investigation Exclusivity
The FDA released draft Q&A guidance that clarifies how drug sponsors can qualify for three‑year non‑patent exclusivity by conducting a “new clinical investigation.” It defines a new study as a human, non‑bioavailability trial whose results have not been previously relied...
Rare Disease Spotlight: Friedreich Ataxia Moves Beyond Mitochondrial Bandages
Friedreich ataxia (FA) received its first FDA‑approved therapy in 2023 when omaveloxolone, marketed as Skyclarys, earned accelerated approval. Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals secured the drug and highlighted the market’s appetite for rare‑disease assets. Skyclarys works by activating the...
Network-Based Prediction of Drug Combinations with Quantum Annealing
The study introduces a quantum‑annealing algorithm that predicts effective drug combinations by casting the problem as a quadratic unconstrained binary optimisation (QUBO). It leverages the network‑medicine concept of disease modules and the “Complementary Exposure” principle, which seeks drugs that hit...
Kian Pee Wan May Be Harmful Due to Hidden Drug Ingredients
The FDA has issued a safety alert warning consumers not to purchase or use Kian Pee Wan, a product marketed as an appetite stimulant and weight‑gain aid. Laboratory testing revealed the supplement contains the prescription steroid dexamethasone and the antihistamine...
CMS Moves Forward with 3rd Round of Medicare Drug Negotiations
CMS announced that the third round of the Medicare Drug Price Negotiation Program will proceed with full manufacturer participation, covering 15 high‑cost, single‑source drugs and one drug slated for renegotiation. The agency will issue initial price offers by June 1, 2026,...
Bacterial Strain Breaks Decades-Old Bottleneck in Chemotherapy Drug Manufacturing
An international research team has engineered a bacterial strain that boosts doxorubicin output by 180% compared with current industrial methods, overcoming three long‑standing bottlenecks—insufficient redox partners, drug‑binding “sponge” proteins, and suboptimal enzyme positioning. The findings, published in Nature Communications, detail...
Bimatoprost Implant Reduces IOP, Improves Vision at 12 Months
SpyGlass Pharma’s Bimatoprost Drug Pad‑IOL System demonstrated significant intra‑ocular pressure (IOP) reductions and vision gains in a phase 1/2 trial of 104 patients with open‑angle glaucoma or ocular hypertension undergoing cataract surgery. At 12 months, the 78 µg dose lowered mean IOP 34%...
FDA Approves Cosentyx for Pediatric Hidradenitis Suppurativa
The U.S. Food and Drug Administration has approved Novartis' secukinumab, marketed as Cosentyx, for adolescents aged 12 and older with moderate‑to‑severe hidradenitis suppurativa (HS). This marks the first IL‑17A inhibitor cleared for a pediatric indication, extending the drug’s adult HS...
Kenai: Off-the-Shelf Parkinson’s Progenitors with Precision Transplant Tech
Kenai, a new allogeneic cell‑therapy company, is developing off‑the‑shelf iPSC‑derived progenitor cells for Parkinson’s disease, paired with a precision brain‑delivery platform that uses real‑time functional imaging. The approach builds on Japan’s recent approvals of iPSC‑based Parkinson’s treatments and aims to...
Jeonbuk National University Researchers Develop DDINet for Drug-Drug Interaction Prediction
Researchers at Jeonbuk National University have unveiled DDINet, a lightweight neural network designed to predict drug‑drug interactions (DDIs) for previously unseen compounds. The model employs five fully‑connected layers and molecular fingerprints, with Morgan fingerprints delivering the best results. Using a...
Search List of Extended Use Dates to Assist with Drug Shortages
The FDA has released a searchable table of extended use dates for specific drug lot numbers, based on manufacturer‑provided stability data. These extensions allow providers and patients to continue using existing stock beyond original expiration dates, helping to mitigate ongoing...
Money Raised by Biopharma
Researchers at INSERM uncovered hypothalamic tanycytes as a previously unknown tau‑clearing pathway, opening fresh therapeutic avenues for Alzheimer’s and related tauopathies. Merck Sharp & Dohme (MSD) announced the synthesis and pre‑clinical testing of novel PET tracers that bind α‑synuclein, aiming...
Shilpa Biologicals, mAbTree Program Targets Immune Pathway in Rare Blood Cancers
Shilpa Biologicals and mAbTree Biologics received FDA orphan drug designation for an investigational monoclonal antibody that targets an immune‑evasion pathway in essential thrombocythemia and polycythemia vera. The designation validates the novel mechanism and accelerates plans for IND‑enabling studies and first‑in‑human...
FDA Drug Safety Podcasts
The FDA’s Center for Drug Evaluation and Research has expanded its Drug Safety Podcast series, delivering concise audio briefings that coincide with official Drug Safety Communications. Recent episodes address serious liver injury linked to Ocaliva, rare hypocalcemia risks with Prolia,...
March 13 Policy Watch: FDA Streamlines Its Process for Approving Biosimilar Drugs
The FDA released draft guidance that lets biosimilar developers use foreign comparator data and, in some cases, replace clinical studies with chemical analysis, potentially cutting development costs by $20 million. Simultaneously, the agency launched the Adverse Event Monitoring System (AEMS), a...
Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster
The J. Craig Venter Institute unveiled a 4D, nanoscale simulation that tracks the entire life cycle of a minimal bacterial cell, marking a milestone for synthetic biology. A new gene‑editing platform designs DNA donors that dodge immune detection, enabling safer,...
Tahoe Therapeutics Builds Record Single-Cell Atlas Using Automated Pipetting Technology
San Francisco biotech Tahoe Therapeutics is building the world’s largest single‑cell atlas of cell‑chemical interactions, leveraging Integra Biosciences’ Assist Plus pipetting robot, Parse Biosciences’ Evercode scRNA‑seq kits, and its own AI analytics. Automation has increased single‑cell preparation throughput more than fivefold...
Federal Drug Price Reforms Are Working, Study Says
A new JAMA Internal Medicine study finds that the Inflation Reduction Act’s 2024 drug‑pricing provisions have reduced cost‑related medication nonadherence among Medicare beneficiaries. Compared with privately insured peers, seniors saw a 4.9‑percentage‑point drop overall and a 7.8‑point decline among those...
Gubra Plots Roivant-Like Model as Partnered Obesity Drugs Take Flight
Gubra, a 300‑employee Danish biotech known for its obesity drug partnerships, announced plans to adopt a Roivant‑style incubation model. The strategy will spin out a series of focused biotech companies, each targeting niche therapeutic areas beyond obesity, such as metabolic...
Can A Single Shot Save Your Heart?
Researchers have developed a self‑amplifying RNA injection that directs skeletal muscle to produce the heart‑healing peptide Nppa, dramatically reducing scar formation in pig models of myocardial infarction. The lipid‑nanoparticle‑delivered RNA sustains protein expression for at least four weeks, far outlasting...
Eurofins CDMO Alphora – Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software
Eurofins CDMO Alphora has launched an AI‑powered software that predicts salt and co‑crystal formation for APIs and intermediates, developed in partnership with a local university. The machine‑learning platform is now a core component of its solid‑state screening programs, delivering highly...
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
Q4 earnings highlighted a mixed biotech landscape, with regulatory turbulence easing for some firms while high‑stakes catalysts loom. Capricor Therapeutics is preparing to resubmit its Duchenne cardiomyopathy cell therapy after the departure of FDA CBER director Vinay Prasad, and reported...
High Altitude Survival Gene Mutation Points to Strategy for Repairing Nerve Damage
Researchers identified a high‑altitude Retsat Q247R mutation that enhances myelin formation under hypoxic stress and accelerates remyelination in mouse models. The variant boosts neuronal production of the vitamin‑A‑derived metabolite ATDR, which activates the RXR‑γ pathway in oligodendrocyte progenitors. Administering ATDR...
Immutep's LAG-3 Drug Fails Phase 3 Lung Cancer Study
Immutep’s LAG‑3 fusion protein eftilagimod‑alpha failed to improve overall survival in a Phase 3 randomized study in non‑small cell lung cancer. The trial, enrolling roughly 600 patients, did not meet its primary endpoint and showed no statistically significant benefit versus standard...
Ultragenyx’s Gene Therapy Hits Key Endpoint in Phase 3 Trial for Blood Ammonia Disease
Ultragenyx announced that its investigational gene therapy for ornithine transcarbamylase (OTC) deficiency met a primary endpoint in a Phase 3 trial involving 37 patients. The study demonstrated a statistically significant reduction in blood ammonia levels, the key marker of disease...
Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate
Orphan‑drug sales are projected to exceed $400 billion by 2032, more than double the 2025 level. Small‑molecule therapies dominate the pipeline, accounting for 45% of the 20 most valuable orphan candidates, signaling a resurgence after years of biologic focus. The Inflation...
Parkinson’s Research Reaches “Pivotal” Stage, but Barriers Remain
Parkinson’s research has entered a pivotal phase, driven by deeper disease insights and advanced models such as patient‑derived iPSCs. Despite a pipeline of potential disease‑modifying therapies, funding shortfalls and outdated trial endpoints continue to impede progress. Parkinson’s UK’s Virtual Biotech...
LabConnect Expands Global Central Laboratory Infra with Wuxi, China Facility
LabConnect announced the grand opening of a new central laboratory in Wuxi, China, expanding its global network to eight sites. The facility, built with Teddy Laboratory (now Frontage Laboratories), integrates LabConnect’s technology‑driven logistics and data oversight with local expertise. It...
Immutep Investors Spooked by LAG-3 Failure in Lung Cancer
Australian biotech Immutep saw its ASX shares tumble more than 88% after the independent data monitoring committee recommended halting its pivotal phase‑3 TACTI‑004 trial of the LAG‑3 inhibitor eftilagimod alfa (efti) in first‑line non‑small cell lung cancer. The trial, which...
Otsuka Pharmaceutical Reports OLE Study Data on Repinatrabit in Phenylketonuria
Otsuka Pharmaceutical disclosed early open‑label extension (OLE) data for repinatrabit (JNT‑517) in adolescents with phenylketonuria (PKU). A 75 mg twice‑daily regimen achieved a 67% mean reduction in blood phenylalanine by day 56, with responses observed across prior sapropterin responders, non‑responders, and a...
Eliquis Proves Safer than Xarelto for Patients with Deep Blood Clots
A head‑to‑head trial published in the New England Journal of Medicine compared Eliquis (apixaban) and Xarelto (rivaroxaban) in patients with deep‑vein thrombosis. The study found Eliquis significantly reduced major bleeding risk while maintaining equal efficacy in preventing clot recurrence. This...
/file/attachments/orphans/JustinandJaylin_364502.jpg)
HEALTH INEQUITY: Red Cross Children’s Hospital Doctor Using Donated ‘Miracle’ Cystic Fibrosis Drug to Save Lives
South Africa’s Red Cross Children’s Hospital is using donated Trikafta, a $300,000‑a‑year cystic fibrosis therapy, to keep seven‑year‑old Jaylin Leitjies alive after his lungs were severely damaged in infancy. The drug, produced by Vertex Pharmaceuticals, is not registered with SAHPRA...
PsiQuantum and National Cancer Center Japan Partner on Quantum Computing
PsiQuantum has signed a research agreement with Japan's National Cancer Center to explore utility‑scale quantum computing for oncology drug discovery. The partnership will focus on developing fault‑tolerant quantum algorithms and clinically relevant applications using PsiQuantum's Construct platform. It also brings...
Pilatus Biosciences Doses First Patient in PLT012 Antibody Trial
Pilatus Biosciences has begun dosing the first patient in a Phase I, open‑label trial of PLT012, its first‑in‑class anti‑CD36 monoclonal antibody, at Next Oncology in Houston. The FDA recently issued IND clearance along with orphan‑drug status for hepatocellular carcinoma and fast‑track...
The Role of AI in Large-Scale Drug Manufacturing: Current Applications and Future Trends
Artificial intelligence is reshaping large‑scale pharmaceutical manufacturing by automating process design, real‑time control, and supply‑chain management. Machine‑learning models can simulate optimal temperature, pressure and reactant levels, accelerating scale‑up and reducing waste. AI‑driven advanced process control continuously adjusts bioreactor conditions, while...